Gene · 2118
Papers2,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and validation of a prognostic risk model based on radiosensitivity-related genes in nasopharyngeal carcinoma. | Transl Oncol | 2025 | 39675252 | PubTator, text mining | PubMed |
| The Role of Pea3 Transcription Factor Subfamily in the Nervous System. | Mol Neurobiol | 2025 | 39269548 | PubTator, text mining | PubMed |
| Pan-cancer analysis of the potential of PEA3 subfamily genes as tumor markers. | Sci Rep | 2024 | 39732961 | PubTator, text mining | PubMed |
| Transcriptomics-informed pharmacology identifies epigenetic and cell cycle regulators that enhance AAV production. | Mol Ther Methods Clin Dev | 2024 | 39687728 | PubTator, text mining | PubMed |
| The capicua-ataxin-1-like complex regulates Notch-driven marginal zone B cell development and sepsis progression. | Nat Commun | 2024 | 39632849 | PubTator, text mining | PubMed |
| Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. | Signal Transduct Target Ther | 2024 | 39627201 | PubTator, text mining | PubMed |
| Elevated ETV4 expression in cholangiocarcinoma is linked to poor prognosis and may guide targeted therapies. | World J Gastrointest Oncol | 2024 | 39554735 | PubTator, text mining | PubMed |
| Transcription factor ETV4 plays a critical role in the development of non-alcoholic fatty liver disease. | Int J Biol Macromol | 2024 | 39500423 | PubTator, text mining | PubMed |
| The pathogenic germline ETV4 P433L mutation identified in multiple primary lung cancer affect tumor stem-like property by Wnt/β-catenin pathway. | Cell Death Dis | 2024 | 39389944 | PubTator, text mining | PubMed |
| Prognostic value of PEA3 subfamily gene expression in cholangiocarcinoma. | World J Gastrointest Oncol | 2024 | 39350976 | PubTator, text mining | PubMed |
| Comprehensive Analysis of the Mechanism of Anoikis in Hepatocellular Carcinoma. | Genet Res (Camb) | 2024 | 39297018 | PubTator, text mining | PubMed |
| Global transcriptomic network analysis of the crosstalk between microbiota and cancer-related cells in the oral-gut-lung axis. | Front Cell Infect Microbiol | 2024 | 39228892 | PubTator, text mining | PubMed |
| Molecular pathogenesis of microsatellite instability-high early-stage colorectal adenocarcinoma in India. | Drug Metab Pers Ther | 2024 | 39042905 | PubTator, text mining | PubMed |
| MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma. | Virchows Arch | 2024 | 38970674 | PubTator, text mining | PubMed |
| Exploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation. | Biomolecules | 2024 | 38927096 | PubTator, text mining | PubMed |
| ETV4 promotes the progression of cholangiocarcinoma by regulating glycolysis via the TGF-β signaling. | Transl Oncol | 2024 | 38878613 | PubTator, text mining | PubMed |
| Biological effect of ETV4 and the underlying mechanism of its regulatory effect on epithelial‑mesenchymal transition in intrahepatic cholangiocarcinoma cells. | Oncol Lett | 2024 | 38872859 | PubTator, text mining | PubMed |
| An oncogenic enhancer promotes melanoma progression via regulating ETV4 expression. | J Transl Med | 2024 | 38849954 | PubTator, text mining | PubMed |
| Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma. | Int Arch Allergy Immunol | 2024 | 38781935 | PubTator, text mining | PubMed |
| ETV4 is a mechanical transducer linking cell crowding dynamics to lineage specification. | Nat Cell Biol | 2024 | 38702503 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2118/papers?page=6